Abstract
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 μg/ plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
He, J. and Whelton, P.K. (1997) Epidemiology and prevention of hypertension. Med. Clin. North Am., 81, 1077–1097.
Whelton, P.K. (1994) Epidemiology of hypertension. Lancet, 344, 101–106.
Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217–223.
Brunner, H.R. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vasc. Health Risk Manage., 2, 327–340.
Fletcher, A.E., Palmer, A.J. and Bulpitt, C.J. (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl., 12, S43–S47.
Vleeming, W., van Amsterdam, J.G., Stricker, B.H. and de Wildt, D.J. (1998) ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf., 18, 171–188.
Warner, G.T. and Jarvis, B. (2002) Olmesartan medoxomil. Drugs, 62, 1354–1356.
Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 285, 181–188.
ECD/OCDE. (1997) OECD guidelines for the testing of chemicals (No. 471), Bacterial Reverse Mutation Test, pp. 1–11.
Norwood, D., Branch, E.I., Smith, B. and Honeywell, M. (2002) Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast., 27, 611–618.
Schwocho, L.R. and Masonson, H.N. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol., 41, 515–527.
Püchler, K., Nussberger, J., Laeis, P., Wittem, P.U. and Brunner, H.R. (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in saltrestricted hypertensive patients. J. Hypertens., 15, 1809–1812.
Brambilla, G. and Martelli, A. (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res., 612, 115–149.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kim, J.W., Ahn, I., Ryu, S.H. et al. Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay. Toxicol Res. 29, 217–219 (2013). https://doi.org/10.5487/TR.2013.29.3.217
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2013.29.3.217